|
Jean-Paul Castaigne
President and CEO
AngioChem, Montréal (Quebec)
|
"AngioChem is a clinical-stage biotechnology company that uses its patented EPiC technology to discover and develop innovative drugs for treating brain diseases. BDC has been a valued partner since our founding and has provided us with much more than just venture capital. Advice, professional contacts, strategic vision and support from BDC have been crucial to our company's progress and development. When BDC is at the table, it means seriousness and professionalism." |